Chinese cancer and autoimmune disease therapy developer Clover Biopharmaceuticals has raised a $43 million Series B round led by local VC Lapam Capital and US private equity firm Delos Capital.
Betta Capital, Sichuan Health Care Industry Fund, Beijing Zhongguancun VC and Jinlong Group also participated. It brings Clover’s total capital raised since 2016 to more than $100 million. Clover is...
Ucommune, China’s largest co-working space player which is considered the local equivalent to troubled US operator WeWork, has filed for a US IPO.
Chinese drone manufacturer EHang traded flat on its NASDAQ debut following a $40 million IPO that priced at the bottom end of the indicative range.
Tiger Global Management has led a $26 million Series B round for Indian B2B financing platform provider KredX.
New Zealand’s Impact Enterprise Fund (IEF) has confirmed an investment in local sustainable packaging supplier Grounded.